TNYA:NASDAQTenaya Therapeutics, Inc. Analysis

Tenaya Therapeutics is trading at $0.79, below its 20‑day SMA of $0.83 and its 200‑day SMA of $1.03, while the 50‑day SMA sits at $0.76, indicating a short‑term price weakness but a longer‑term downtrend. The RSI of 48.7 suggests the stock is neither overbought nor oversold, and the MACD histogram is negative, confirming a bearish momentum signal. However, the stock’s 30‑day volatility is extreme at 91.8% and its beta of ~2.9 makes it highly responsive to market swings, amplifying both upside and downside risk.
On the fundamentals side, Tenaya holds $80.9 M in cash against a modest $10.1 M debt load, but it is burning cash at roughly $64 M annually and reports no meaningful revenue, resulting in deep operating losses. Despite a negative PE and a price‑to‑sales multiple of 764×, analysts rate the stock a “strong_buy” with a mean target of $4.00, implying a potential upside of over 400%. Recent earnings showed a modest surprise (+4.3%) and the company is set to present Phase 1b/2 data for its TN‑401 gene therapy at ASGCT 2026, which could serve as a catalyst for price appreciation.